Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence

Eli Lilly and Company (LLY) announced a definitive agreement to acquire Waltham, MA-based small biotech Morphic Therapeutics (MORF) for approximately $3.2 billion. The acquisition will expand Lilly’s pipeline in immunology, a core area for the company, by adding Morphic’s oral integrin therapies for treating serious chronic diseases.Morphic's lead pipeline candidate is MORF-057, an oral α4β7 inhibitor with the potential to improve outcomes in treating inflammatory bowel disease (IBD). The integrin, α4β7, ha ...